



Prior Authorization Criteria

REZDIFFRA™ (*resmetirom*) PA CRITERIA:

REZDIFFRA™ (*resmetirom*) is a thyroid hormone receptor-beta (THR-beta) agonist indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) [formerly known as nonalcoholic steatohepatitis (NASH)] with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).

Prior authorization is required for REZDIFFRA™ (*resmetirom*). Prior authorization approval will be considered when the following criteria are met. Along with the Universal PA Form, please submit any supporting clinical documentation.

Initial Authorization: 12 months

1. Age of the patient is within the age range as recommended by the FDA label; **AND**
2. Patient has a diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) [formerly known as nonalcoholic steatohepatitis (NASH)] with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) that has been confirmed by clinical presentation along with laboratory findings and/or imaging and/or biopsy results; **AND**
3. Patient does NOT have decompensated cirrhosis; **AND**
4. Prescribed by or in consultation with a gastroenterologist or hepatologist; **AND**
5. Prescriber attests that REZDIFFRA™ will be used in conjunction WITH diet and exercise and WITHOUT excessive alcohol consumption; **AND**
6. Prescribed dosage does NOT exceed one REZDIFFRA™ tablet by mouth once daily.

Re-Authorization: 12 months

1. Patient continues to meet initial authorization requirements; **AND**
2. Documentation of positive clinical response to therapy (e.g., improvement or stabilization of fibrosis); **AND**
3. Prescribed dosage does NOT exceed one REZDIFFRA™ tablet by mouth once daily.



REZDIFFRA™ Dosing:

- The recommended dosage of REZDIFFRA™ is based on actual body weight. For patients weighing:
 - < 100 kilograms, the recommended dose is 80 mg orally once daily
 - ≥ 100 kilograms, the recommended dose is 100 mg orally once daily
- If REZDIFFRA™ is used concomitantly with a moderate CYP2C8 inhibitor, reduce the dosage as outlined below.
 - For actual body weight < 100 kilograms, reduce the dosage of REZDIFFRA™ to 60 mg orally once daily.
 - For actual body weight ≥ 100 kilograms, reduce the dosage of REZDIFFRA™ to 80 mg orally once daily.

Formulation:

- Available as 60 mg, 80 mg, and 100 mg oral tablets